Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
World game at war: why some European nations have threatened a World Cup boycott 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
PARSIPPANY, N.J., April 26, 2018 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S. markets on Thursday, May 3, 2018. The announcement will be followed by a conference call at 8:30 a.m. ET. Participating in the call from Pacira will be Dave Stack, chairman and chief executive officer, and other members of the company’s senior management team.
The call can be accessed by dialing 1-877-845-0779 (domestic) or 1-720-545-0035 (international) ten minutes prior to the start of the call and providing the Conference ID 6585169. A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and providing the Conference ID 6585169. The replay of the call will be available for one week from the date of the live call.
The live, listen-only webcast of the conference call can also be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the call.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Investor Contact: Pacira Pharmaceuticals, Inc. Christian Pedetti, (973) 254-4387 [email protected]
